Redefining thalassemia as a hypercoagulable state

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 231-236

  Cappellini, M Domenica ^a   Motta, Irene ^a   Musallam, Khaled M ^b   Taher, Ali T ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

hypercoagulability; stroke; thalassemia; thromboembolism

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANKYRIN; CD63 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROCYTE BAND 3 PROTEIN; HEMOGLOBIN F; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PADGEM PROTEIN; PROSTACYCLIN; SPECTRIN; THROMBOXANE A2; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BETA THALASSEMIA; BLOOD TRANSFUSION; CONFERENCE PAPER; ERYTHROCYTE; FOLLOW UP; HEMOLYSIS; HUMAN; HYPERCOAGULABILITY; SICKLE CELL ANEMIA; SPLENECTOMY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE LIFESPAN; THROMBOEMBOLISM; THROMBOSIS; URINARY EXCRETION;

EID: 77955894491     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05548.x     Document Type: Conference Paper

References (46)

1. Weatherall, D.J. & J.B. Clegg. 2001. The Thalassaemia Syndromes, 4th edn. Blackwell Science. Oxford.
2. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 2004. Survival and complications in patients with thalassemiamajor treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
3. Taher, A.T.,Z.K.Otrock, I.Uthman&M.D.Cappellini. 2008. Thalassemia and hypercoagulability. Blood Rev. 22: 283-292.
4. Taher, A.,H. Ismaeel&M.D. Cappellini. 2006. Thalassaemia intermedia: revisited. Blood Cells Mol. Dis. 37: 12-20.
5. Winichagoon, P., S. Fucharoen&P.Wasi. 1981. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J. Trop. Med. Public Health 12: 556-560.
6. Del Principe, D., A. Menichelli, S. Di Giulio, et al. 1993. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br. J. Haematol. 84: 111-117.
7. Ruf,A., M. Pick,V.Deutsch, et al. 1997. In vivo platelet activation correlateswith red cell anionic phospholipid exposure in patientswith beta-thalassaemia major.Br. J.Haematol. 98: 51-56.
8. Eldor, A., Y. Krausz, H. Atlan, et al. 1989. Platelet survival in patients with beta-thalassemia. Am. J. Hematol. 32: 94-99.
9. Eldor, A., F. Lellouche, A. Goldfarb, et al. 1991. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 77: 1749-1753.
10. Rund,D.&E.Rachmilewitz. 2005. Beta-thalassemia. N.Engl. J. Med. 353: 1135-1146.
11. Shinar, E, E.A. Rachmilewitz & S.E. Lux. 1989. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J. Clin. Invest. 83: 404-410.
12. Hershko, C., G. Graham, G.W. Bates & E.A. Rachmilewitz. 1978. Nonspecific serum iron in thalassaemia: an abnormal serumiron fraction of potential toxicity.Br. J. Haematol. 40: 255-263.
13. Kuypers, F.A. & K. de Jong. 2004. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell. Mol. Biol. 50: 147-158.
14. Tavazzi, D., L. Duca, G. Graziadei, et al. 2001. Membranebound iron contributes to oxidative damage of betathalassaemia intermedia erythrocytes. Br. J. Haematol. 112: 48-50.
15. Borenstain-Ben Yashar, V., Y. Barenholz, et al. 1993. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am. J. Hematol. 44: 63-65.
16. Helley, D., A. Eldor, R. Girot, et al. 1996. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb. Haemost. 76: 322-327.
17. Atichartakarn, V., P. Angchaisuksiri, K. Aryurachai, et al. 2002. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br. J. Haematol. 118: 893-898.
18. Chen, S., A. Eldor, G. Barshtein, et al. 1996. Enhanced aggregability of red blood cells of beta-thalassemiamajor patients. Am. J. Physiol. 270: H1951-H1956.
19. Butthep, P., A. Bunyaratvej, Y. Funahara, et al. 1995. Alterations in vascular endothelial cell related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb. Haemost. 74: 1045-1049.
20. Butthep, P., A. Bunyaratvej, Y. Funahara, et al. 1997. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J. Trop. Med. Public Health 28: 141A-148A.
21. Hovav, T., A. Goldfarb, G. Artmann, et al. 1999. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br. J. Haematol. 106: 178-181.
22. Butthep, P., S. Rummavas, R.Wisedpanichkij, et al. 2002. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am. J. Hematol. 70: 100-106.
23. Carlos, T.M. & J.M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101.
24. Mann, K.G., C. van't Veer, K. Cawthern & S. Butenas. 1998. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul. Fibrinolysis 9: S3-S7.
25. Habib, A., C. Kunzelmann, W. Shamseddeen, et al. 2008. Elevated levels of circulating procoagulant microparticles in patients with thalassemia intermedia. Haematologica 93: 941-942.
26. Taher, A., H. Isma'eel, G. Mehio, et al. 2006. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in theMediterranean area and Iran. Thromb. Haemost. 96: 488-491.
27. Cappellini, M.D., L. Robbiolo, B.M. Bottasso, et al. 2000. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br. J. Haematol. 111: 467-473.
28. Cappellini, M.D., E. Grespi, E. Cassinerio, et al. 2005. Coagulation and splenectomy: an overview. Ann. N.Y. Acad. Sci. 1054: 317-324.
29. Atichartakarn, V., P. Angchaisuksiri, K. Aryurachai, et al. 2003. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int. J. Hematol. 77: 299-303.
30. Zalloua, P.A., H. Shbaklo, Y.A. Mourad, et al. 2003. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb. Haemost. 89: 767-768.
31. Iolascon, A., P. Giordano, S. Storelli, et al. 2001. Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica 86: 1112-1113.
32. Giordano, P., M. Galli, G.C. Del Vecchio, et al. 1998. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br. J. Haematol. 102: 903-906.
33. Zurlo, M.G., P. De Stefano, C. Borgna-Pignatti, et al. 1989. Survival and causes of death in thalassaemia major. Lancet 2: 27-30.
34. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 2004. Survival and complications in patients with thalassemiamajor treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
35. Borgna Pignatti, C., V. Carnelli, V. Caruso, et al. 1998. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 99: 76-79.
36. Logothetis, J.,ConstantoulakisM, Economidou J, et al. 1972. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 22: 294-304.
37. Manfre, L., E. Giarratano, A. Maggio, et al. 1999. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am. J. Roentgenol. 173: 1477-1480.
38. Taher, A.T., K.M. Musallam, W. Nasreddine, et al. 2009. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J. Thromb. Haemost. doi: 10.1111/j.1538- 7836.2009.03651.x [Epub ahead of print]
39. Michaeli J, M. Mittelman, D. Grisaru & E.A. Rachmilewitz. 1992. Thromboembolic complications in beta thalassemia major. Acta Haematol. 87: 71-74.
40. Gillis, S, M.D. Cappellini, A. Goldfarb, et al. 1999. Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica 84: 959-960.
41. van Teunenbroek, A., F.A. Wijburg, J.W. ten Cate, et al. 1989. Thromboembolic complications in an asplenic HbE- thalassaemia patient.Neth. J. Med. 35: 123-127.
42. Sonakul, D., P. Pacharee, T. Laohapand, et al. 1980. Pulmonary artery obstruction in thalassaemia. Southeast Asian J. Trop. Med. Public Health 11: 516-523.
43. Sumiyoshi, A., K. Thakerngpol & D. Sonakul. 1992. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J. Trop. Med. Public Health 23(Suppl. 2): 29-31.
44. Ataga, K.I., M.D. Cappellini & E.A. Rachmilewitz. 2007. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139: 3-13.
45. Karimi, M., H. Darzi & M. Yavarian. 2005. Haematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J. Pediatr. Hematol. Oncol. 27: 380-385.
46. Tripodi A., M.D. Cappellini, V. Chantarangkul, et al. 2009. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica 94: 1520-1527.